Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most safety-related claims (muscle injury/rhabdomyolysis, liver enzyme changes, and common discontinuation adverse reactions) are supported by the provided label excerpts, but several statements are broader than what the excerpts explicitly confirm (e.g., 'doctors generally focus on' muscle vs liver; examples of commonly reported side effects beyond what the excerpts list; and guidance wording about risk-factor tailoring/urgent care is not directly stated).
Category Scores
Accurate Statements
Lipitor (atorvastatin) can rarely cause serious muscle injury.
Section 5.1: 'Rare cases of rhabdomyolysis with acute renal failure... reported with LIPITOR...'
Lipitor (atorvastatin) can cause liver enzyme changes.
Section 5.2: 'Statins... associated with biochemical abnormalities of liver function.' Section 6.1: '... alanine aminotransferase increase (0.4%), and hepatic enzyme increase (0.4%).'
Symptoms consistent with serious statin reactions, especially significant muscle pain/weakness or signs of liver trouble, warrant contacting a doctor promptly or seeking urgent care.
Section 5.1 includes serious skeletal muscle outcomes (rhabdomyolysis). Section 5.2 describes persistent transaminase elevations. The excerpts do not provide the exact 'urgent care' instruction, but the presence of serious muscle and liver warnings is supported.
Unsupported Statements
Doctors generally focus on muscle-related problems as important safety side effects for statins.
The excerpts state muscle risks (rhabdomyolysis/myopathy) but do not state how 'doctors generally focus' or comparative emphasis.
Doctors generally focus on liver-related issues as important safety side effects for statins.
The excerpts state liver dysfunction/biochemical abnormalities but do not state how 'doctors generally focus' or comparative emphasis.
Common milder side effects some patients report with Lipitor (atorvastatin) include digestive symptoms or headache.
Section 6.1 lists adverse reactions leading to discontinuation at >placebo: myalgia, diarrhea, nausea, alanine aminotransferase increase, hepatic enzyme increase. 'Headache' is not included in the provided excerpt list.
Doctors can tailor their discussion of Lipitor (atorvastatin) side effects to risk factors such as age, other medicines, liver history, or muscle symptoms.
The excerpts mention risk in the context of drug interactions (e.g., higher doses with certain drugs such as cyclosporine/strong CYP3A4 inhibitors) and do discuss muscle/liver risks, but they do not provide guidance about tailoring discussions by age/liver history/muscle symptoms as a general practice.
Doctors may summarize side effects rather than read every entry from the label.
No language in the provided excerpts addresses how clinicians should present or summarize labeling content.
Doctors should be able to describe key side effects and direct patients to the full side-effect list in official documents such as the patient medication guide or full prescribing information.
The provided excerpts do not include instructions about patient counseling materials or directing patients to specific documents.
Contradictions
Important Omissions
The label includes specific contraindication and precautions (e.g., pregnancy contraindication) and particular interaction counseling (e.g., grapefruit juice and increased plasma concentrations with excessive consumption) that are not mentioned in the claims.
Importance:
Moderate
Specific adverse reactions leading to discontinuation at >placebo are provided in the excerpt (myalgia, diarrhea, nausea, ALT increase, hepatic enzyme increase) but the claim set adds 'headache' which is not supported by the excerpt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Key serious muscle and liver warnings are directionally consistent with the label excerpts, but multiple counseling/priority and side-effect frequency claims are broader than the provided label, and one added example ('headache') is not supported by the listed adverse reactions in the excerpt.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several statements go beyond the provided label excerpts (comparative 'doctor focus' assertions, counseling/label-reading guidance, and inclusion of 'headache' not supported by the adverse-reaction excerpt).
Suggested Improvement
Limit statements to label-supported facts from the excerpts (e.g., rare rhabdomyolysis; biochemical liver function abnormalities and specific discontinuation adverse reactions listed; and avoid unsourced claims about clinician emphasis or counseling practices). If discussing urgent evaluation, align language more closely with the label’s stated serious muscle/liver risks rather than adding specific instruction details not present in the excerpt.